Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to devel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rodrigo Nalio Ramos, Virginia Picanço-Castro, Theo Gremen M. Oliveira, Alfredo Mendrone, Junior, Gil Cunha De Santis, Martin Hernan Bonamino, Vanderson Rocha
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/558a6b96477e4bcba2af415589f2cdde
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!